Company / Operating Cash Flow
Cardiff Oncology, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$37.9M
FY2025
5-year range
-$37.9M / -$16.3M
FY2021-FY2025
Trend
-22.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$38M in FY2025 to -$13M in FY2016.
Based on SEC 10-K filings.
-$38M in FY2025.
Declined from -$34M to -$38M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 22.8% year-over-year.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$37.9M | -22.8% |
| FY2024 | -$30.9M | +8.7% |
| FY2023 | -$33.8M | -46.8% |
| FY2022 | -$23.0M | -41.2% |
| FY2021 | -$16.3M | +0.0% |
| FY2020 | -$16.3M | -23.0% |
| FY2019 | -$13.3M | +43.0% |
| FY2018 | -$23.3M | +25.0% |
| FY2017 | -$31.0M | -143.9% |
| FY2016 | -$12.7M | +42.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026